New treatment for a specific type of sarcoma using a small molecule inhibitor
Official title: Development of a novel small molecule MDM2 inhibitor for innovative sarcoma treatment
Funded at Lamassu Bio INC · NIH-10900571 · Data updated 2026-11-12
This study is testing a new drug called SA53 to see if it can help people with soft tissue sarcoma, especially those who haven't had success with other treatments, by finding the right dose and understanding how it works in the body.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lamassu Bio INC NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | August 7, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $723,169 |
| NIH project number | 5R44CA281622-02 |
| Project ID | NIH-10900571 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with p53 wild type soft tissue sarcomas who have not responded to standard treatments.
✕Less likely to help
Patients with sarcomas that do not have the p53 wild type mutation may not benefit from this research.
What this research studies
This research focuses on developing a new drug, SA53, that targets p53 wild type sarcomas, a type of cancer. The team has conducted extensive testing to ensure the drug is safe and effective, and they plan to conduct a clinical trial to determine the best dose for patients. The trial will also assess how the drug works in the body and its potential to help patients with soft tissue sarcoma. If successful, this innovative treatment could provide a new option for patients who have not responded to other therapies.
Why it matters
Potential benefit: If successful, this research could offer a novel and effective treatment option for patients with p53 wild type soft tissue sarcomas.
How similar studies have gone: Other research has shown promise with similar approaches targeting p53 pathways, indicating potential for success in this novel treatment.
Where this research is happening
-
Lamassu Bio INC
Durham, United States Active
Researchers
- Principal investigator: Hanna, Gabi — Lamassu Bio INC
- Study coordinator: Hanna, Gabi
Related research
Other NIH-funded projects on the same topics.
-
Testing new therapies for pediatric and young adult sarcoma, kidney, and liver cancers
Researchers are testing new drugs and smart combinations in models of pediatric cancers to help guide future treatments for kids and young adults.
-
Precision 3D Imaging to Monitor Kaposi Sarcoma (KS) with SkinScan3D
A new portable 3D imaging tool called SkinScan3D will help doctors measure KS skin lesions more accurately and quickly, especially in people living with HIV.
-
Precision 3D Imaging to Track Kaposi Sarcoma (KS) with SkinScan3D
A new 3D imaging tool called SkinScan3D helps doctors monitor Kaposi sarcoma lesions more accurately and quickly, especially in settings with high KS burden like East Africa and in U.S. clinics with HIV patients.
-
Rapid, bedside KS diagnosis in Africa with KS-COMPLETE
A fast, point-of-care test using skin biopsies to diagnose Kaposi’s sarcoma in sub-Saharan Africa, helping patients get results in about an hour.
-
Kaposi Sarcoma care and research in Africa during ART era
A collaborative program to better understand and improve diagnosis, treatment, and prevention of Kaposi sarcoma for people living with HIV in Zambia and Tanzania.
-
Kaposi Sarcoma in Africa: ART Era Research Network
A collaborative program in Africa and the United States will study Kaposi sarcoma in people living with HIV on ART to improve diagnosis, treatment, and prevention.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.